Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?Zacks Investment Research • 09/04/25
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)PRNewsWire • 09/03/25
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferencePRNewsWire • 09/02/25
Investing in the Age of Longevity: Silver Economy Stocks in FocusZacks Investment Research • 09/01/25
5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or LongerThe Motley Fool • 08/31/25
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?Zacks Investment Research • 08/29/25
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for DepressionZacks Investment Research • 08/26/25
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry PipelinePRNewsWire • 08/25/25